Kothary Nishita, Heit Jeremy J, Louie John D, Kuo William T, Loo Billy W, Koong Albert, Chang Daniel T, Hovsepian David, Sze Daniel Y, Hofmann Lawrence V
Division of Interventional Radiology, Stanford University Medical Center, 300 Pasteur Dr, H3652, Stanford, CA 94305-5642, USA.
J Vasc Interv Radiol. 2009 Feb;20(2):235-9. doi: 10.1016/j.jvir.2008.09.026. Epub 2008 Nov 18.
To evaluate the safety and technical success rate of percutaneous fiducial marker implantation in preparation for image-guided radiation therapy.
From January 2003 to January 2008, we retrospectively reviewed 139 percutaneous fiducial marker implantations in 132 patients. Of the 139 implantations, 44 were in the lung, 61 were in the pancreas, and 34 were in the liver. Procedure-related major and minor complications were documented. Technical success was defined as implantation enabling adequate treatment planning and computed tomographic simulation.
The major and minor complication rates were 5% and 17.3%, respectively. Pneumothorax after lung implantation was the most common complication. Pneumothoraces were seen in 20 of the 44 lung implantations (45%); a chest tube was required in only seven of the 44 lung transplantations (16%). Of the 139 implantations, 133 were successful; in six implantations (4.3%) the fiducial markers migrated and required additional procedures or alternate methods of implantation.
Percutaneous implantation of fiducial marker is a safe and effective procedure with risks that are similar to those of conventional percutaneous organ biopsy.
评估在图像引导放射治疗准备过程中经皮植入基准标记物的安全性和技术成功率。
回顾性分析2003年1月至2008年1月期间132例患者的139次经皮基准标记物植入情况。139次植入中，44次在肺部，61次在胰腺，34次在肝脏。记录与操作相关的主要和次要并发症。技术成功定义为植入能够进行充分的治疗计划和计算机断层扫描模拟。
主要并发症发生率为5%，次要并发症发生率为17.3%。肺部植入后气胸是最常见的并发症。44次肺部植入中有20次（45%）出现气胸；44次肺部移植中仅7次（16%）需要放置胸管。139次植入中，133次成功；6次植入（4.3%）中基准标记物移位，需要额外操作或采用其他植入方法。
经皮植入基准标记物是一种安全有效的操作，其风险与传统经皮器官活检相似。
